Dapagliflozin Propanediol
Brand names: Farxiga, Dapagliflozin
Part of: SGLT2 diabetes & heart drugs
At a glance
- Medicare prescriptions, 2024
- 5,133,706
- Medicare drug cost
- $4.68B
- Average cost per prescription
- $912
- Clinicians who prescribed it
- 111,566
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. • FARXIGA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2. FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 23.0%
- Internal Medicine 21.4%
- Nurse Practitioners 18.0%
- Nephrology (Kidney) 9.7%
- Cardiology 7.5%
- Endocrinology & Diabetes 6.5%
- Physician Assistants 5.2%
- Interventional Cardiology 2.5%
- General Practice 2.0%
- Heart Failure & Transplant Cardiology 1.2%
- Geriatric Medicine 0.9%
- Cardiac Electrophysiology 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 838% from 2019 to 2024.
Biggest change by state since 2019
- Arizona +1,484%
- Florida +1,353%
- Virginia +1,322%
- Georgia +1,244%
- Alabama +1,107%
- Iowa (smallest change) +539%
- Kansas (smallest change) +553%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
AstraZeneca Pharmaceuticals LP
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | yellow round tablet, 7 mm | 5 1427 |
| 10 mg | yellow diamond tablet, 11 mm | 10 1428 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | yellow round tablet, 7 mm | 5 1427 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $3.2M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AstraZeneca Pharmaceuticals LP $3.1M
- AstraZeneca UK Limited $71,130
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.